Pressure put on NHS by the UK medical and patient communities bore fruit last week when NHS England finally agreed to amend its Commissioning Policy for Nusinersen Expanded Access Programme so as to include all those with SMA type 1.
Spain announced that Spinraza will be available to the majority of people with spinal muscular atrophy under the Spanish healthcare system.
Biogen has provided the following community statement on the final results from CHERISH, a Phase 3 study of SPINRAZA.
Today the government of Norway agreed to fund Spinraza (nusinersen) treatment for all patients with SMA under 18 years.
Today members of TreatSMA and their children attended a Fast Track Treatment Campaign meeting organised by Muscular Dystrophy UK at the House of Commons.